European Medicines Agency Validates Marketing Authorization Application for Tisotumab Vedotin in Treating Recurrent or Metastatic Cervical Cancer

Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) have announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for tisotumab vedotin, an antibody-drug conjugate…

Read MoreEuropean Medicines Agency Validates Marketing Authorization Application for Tisotumab Vedotin in Treating Recurrent or Metastatic Cervical Cancer

Verification of Gamma Wave Synchronization in the Human Brain via Auditory Stimulation: Academic Session at Neuroscience 2023 in the United States

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; referred to as “Shionogi”) has revealed that Pixie Dust Technologies, Inc. (Head Office: Tokyo, Japan; Representative…

Read MoreVerification of Gamma Wave Synchronization in the Human Brain via Auditory Stimulation: Academic Session at Neuroscience 2023 in the United States

Advanced Cell Diagnostics by Bio-Techne Establishes a New Benchmark in Spatial Biology with Protease-Free RNAscope Multiomics

Bio-Techne Corporation (NASDAQ: TECH) has unveiled a groundbreaking achievement, as its spatial biology brand, Advanced Cell Diagnostics (ACD), sets a new industry standard. The innovation comes in the form of…

Read MoreAdvanced Cell Diagnostics by Bio-Techne Establishes a New Benchmark in Spatial Biology with Protease-Free RNAscope Multiomics

Atara Biotherapeutics and Pierre Fabre Laboratories Release Phase 3 ALLELE Tab-cel® Results in The Lancet Oncology

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre…

Read MoreAtara Biotherapeutics and Pierre Fabre Laboratories Release Phase 3 ALLELE Tab-cel® Results in The Lancet Oncology

ROHTO Pharmaceutical Forges Global Aesthetics Market Entry Through Long-Term Strategic and Equity Partnership with EMA Aesthetics

ROHTO Pharmaceutical Strengthens Global Presence with EMA Aesthetics Through Strategic Partnership EMA Aesthetics, a Dublin-based global aesthetics company, has announced a significant strategic and equity collaboration with ROHTO Pharmaceutical, a…

Read MoreROHTO Pharmaceutical Forges Global Aesthetics Market Entry Through Long-Term Strategic and Equity Partnership with EMA Aesthetics

Vivet Therapeutics Secures EUR 4.9 Million to Progress Development of Gene Therapy Targeting Cerebrotendinous Xanthomatosis

Vivet Therapeutics Secures EUR 4.9 Million Government Funding for Gene Therapy Advancement in Cerebrotendinous Xanthomatosis Treatment” Vivet Therapeutics, a biotech company specializing in gene therapies for rare inherited metabolic disorders,…

Read MoreVivet Therapeutics Secures EUR 4.9 Million to Progress Development of Gene Therapy Targeting Cerebrotendinous Xanthomatosis